Sennoside A
(Synonyms: 番泻苷 A) 目录号 : GN10001
A dianthrone glycoside with laxative and gastroprotective activities
Cas No.:81-27-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: N/A
Sennoside A is a dianthrone glycoside isolated from Rhei Rhizoma and senna leaf. Sennoside A and B have identical molecular weights and formulae. Sennosides were known as laxatives causing purgative actions through the biotransformation of rhein anthrone. Sennoside A was reported to have regionally differential effects on spontaneous contractions of colon.
In vitro: The gastroprotective activities of sennoside A was found to be due to the up-regulation of PGE2 and the inhibitions of H+/K+-ATPase activity. When measured the H+/K+-ATPase activities of sennoside A, the positive control exhibited inhibitions of 41.1% and 42.4% at 50 μM and 100 μM, whereas sennoside A showed dose-dependent inhibitions of 17.3% and 27.1% at 50 μM and 100 μM [1].
In vivo: In a rat model, sennoside A reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A increased PGE2 in a concentration-dependent manner. Moreover, in the intestinal transporting and gastric emptying rate experiment, sennoside A was found to accelerate such GI motility. These results suggested sennoside A possessed significant gastroprotective activities and it might be useful for the gastric disease treatment [1].
Clinical trial: N/A
Reference:
[1] In Young HwangandChoon Sik Jeong. Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2and the Inhibition of H+/K+-ATPase Biomol Ther (Seoul). 2015 Sep; 23(5): 458–464.
| Cas No. | 81-27-6 | SDF | |
| 别名 | 番泻苷 A | ||
| 化学名 | (9R)-9-[(9R)-2-carboxy-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid | ||
| Canonical SMILES | C1=CC2=C(C(=C1)OC3C(C(C(C(O3)CO)O)O)O)C(=O)C4=C(C2C5C6=C(C(=CC=C6)OC7C(C(C(C(O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O | ||
| 分子式 | C42H38O20 | 分子量 | 862.74 |
| 溶解度 | ≥ 39.9mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1591 mL | 5.7955 mL | 11.591 mL |
| 5 mM | 0.2318 mL | 1.1591 mL | 2.3182 mL |
| 10 mM | 0.1159 mL | 0.5795 mL | 1.1591 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。